Zenas BioPharma Stock Slips as a June Catalyst Moves Into View
Zenas BioPharma shares fell 1.3% to $18.73 on Tuesday, underperforming the biotech sector ahead of a June 4 presentation of Phase 3 data for its autoimmune drug obexelimab. The trial showed a 56% reduction in IgG4-RD flare risk, below Amgen’s Uplizna, which cut risk by 87%. Zenas plans to seek FDA approval this quarter. Investors remain cautious as the stock trades well below its 52-week high.
